Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.91 USD

1.91
684,092

+0.14 (7.91%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1.92 +0.01 (0.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up

Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.

    Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong

    Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.

      Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top

      In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.

        Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4

        Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.

          McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View

          Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.

            Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid

            Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.

              IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues

              IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.

                4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now

                Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.

                  Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands

                  Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands

                    QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View

                    QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.

                      Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines

                      Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.

                        Stryker (SYK) Beats Earnings and Revenue Estimates in Q4

                        Stryker's (SYK) Q4 results benefit from Mako product platform and higher organic sales.

                          Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance

                          Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.

                            Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales

                            Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.

                              Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Sales Beat (Revised)

                              Zimmer Biomet (ZBH) rides high on Hip and S.E.T segments in Q4.

                                Hill-Rom (HRC) Beats Q1 Earnings and Revenues, Margins Up

                                Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q1.

                                  Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3

                                  Abaxis (ABAX) Q3 earnings gain on strength in Medical and Veterinary segments.

                                    Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top

                                    Radixact System and major software overhaul drive Accuray (ARAY) in Q2.

                                      Varian Gains Ground on New Applications, Grows in Australia

                                      Varian's (VAR) innovative product pipeline will continue to drive growth over the long term.

                                        Varian to Open Facility in Brazil, Global Growth in Focus

                                        Varian's (VAR) strong overseas presence is likely to fortify its foothold in the emerging markets. The recent initiative would boost its presence in Latin America.

                                          Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates

                                          Accuray (ARAY) rides high on its product and service segments in Q1.

                                            Why Is Accuray (ARAY) Up 9.9% Since the Last Earnings Report?

                                            Accuray (ARAY) reported earnings about 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              Accuray (ARAY) Grapples With Falling Margin and Product Mix

                                              Accuray Inc.'s (ARAY) low product margins and unfavorable product mix will continue to be a drag on the company's performance.

                                                Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat

                                                Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.

                                                  Accuray's Radixact Now Used by Boise Summit Cancer Center

                                                  Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.